BMS, Takeda's Chinese partners file for IPOs, sending Ascentage, Biokin and Bao bundling toward listings

A trio of Chinese biotechs have filed to go public, setting the stage for offerings that could fill the coffers of companies that have big deals with Bristol Myers Squibb and Takeda.